(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...
AstraZeneca said the deal will build on its expertise in respiratory syncytial virus (RSV), strengthening its vaccines & immune therapies late-stage pipeline with Icosavax's lead investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback